Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Pfizer Hunt for Markers Linked to Pulmonary Disease

SAN FRANCISCO, Jan. 27 - Ciphergen Biosystems said today it expanded its relationship with Pfizer to conduct protein biomarker studies.


Ciphergen will work with Pfizer in a hunt for markers from human serum for early detection of chronic obstructive pulmonary disease, according to Ciphergen. The studies will take place at Ciphergen's BiomarkerDiscoveryCenterin Copenhagen. The deal is with Pfizer's experimental medicine group in France.


Financial details of the agreement were not disclosed.


In 2001, Ciphergen and Pfizer began a study to look for biomarkers associated with drug safety.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.